About Curonz 

Curonz is a clinical stage biotechnology company with a patent portfolio and platform of peptide / peptidomimetic drugs relevant for the treatment of severe neurodegenerative diseases.

With our highly experienced neuroscientists and advisors we intend to develop our drugs with the highest possible benefit to cost ratio. Dr Sieg was formerly the Principal Scientist/Team Leader of Gene Discovery and In vitro Systems at Neuren Pharmaceuticals Ltd where he headed the drug development program over a period of 7 years.

Our ultimate aim is to contribute to the development of effective treatments for some of the most seriously debilitating central nervous system diseases and conditions.

Business Overview

  • Drug candidates: Neural Regeneration Peptides (NRPs) of synthetic origin, classified as NCEs.
  • In 2017, the clinical compound NRP2945 completed a Clinical Phase I study (healthy volunteers) in Melbourne and all associated reports have been completed.
  • In 2019, completed a successful small proof of concept study in 4 drug-resistant patients with typical absence epilepsy showing a decrease iminishing of seizures and an increase in seizure freedom.
  • In 2022, once the IND is approved NRP2945 will be studied for refractory epilepsy in children diagnosed with Lennox-Gastaut Syndrome (LGS) - Phase II clinical study.
  • Internationally granted patent claims for NRP2945 and other NRPs directed to neural regeneration and protection as well as seizure control regarding the central nervous system.
  • Unique mechanism of action which produces both regeneration of CNS tissue and anti-inflammatory effects while fast regulating GABA A receptor subunit composition.
  • Support from the General US-based Fast Forward fund (MS society), from the New Zealand government and private equity investment up to IND.
  • Applied for Orphan drug designation and potential for breakthrough status for NRPs.

These exciting peptides have proven efficacy within various neurodegenerative animal disease models indicating significant future therapeutic effects for several human central neural system diseases which currently have few or no treatments and potentially other applications.

Our drug candidate has huge potential to contribute to unmet medical need in epileptic encephalopathies as well as other severe neurological diseases, however, we need a pharma partner or clinical phase II investment to enable us to achieve our technical and commercial goals.